Yondelis for Liposarcoma or Leiomyoscarcoma – Details


( Last Updated : August 22, 2016)
Generic Name:
Trabectedin
Project Status:
Complete
Therapeutic Area:
Metastatic Liposarcoma or Leiomyosarcoma
Manufacturer:
Janssen Inc.
Brand Name:
Yondelis
Project Line:
Reimbursement Review
Project Number:
PC0071-000
NOC Date:

Details

Strength:
1mg/vial
Tumour Type:
Sarcoma
Indications:
Metastatic Liposarcoma or Leiomyosarcoma
Funding Request:
For the treatment of patients with metastatic liposarcoma or leiomyosarcoma after failure of prior anthracycline and ifosfamide chemotherapy
Review Status:
Complete
Sponsor:
Janssen Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary

Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – pERC Final Recommendation

Final Recommendation
August 5, 2016

Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – Final Clinical Guidance Report

Guidance Reports
June 3, 2016

Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – Final Economic Guidance Report

Guidance Reports
June 3, 2016

Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – pERC Initial Recommendation

Initial Recommendation
June 3, 2016

Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – PAG Feedback on Initial Recommendation

Feedback
August 5, 2016

Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – Manufacturer Feedback on Initial Recommendation

Feedback
August 5, 2016

Trabectedin (Yondelis) for Liposarcoma or Leiomyoscarcoma – Patient Advocacy Group COI Declarations

COI Declarations
August 5, 2016

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.